However, co-treatment with conatumumab and TRAIL did not supersede resistance to apoptosis in all cancer cells, again suggesting that tissue-specific considerations must be taken into account, and the addition of TRAIL to other TRAIL DR antibody agonists did not overcome the requirement for additional crosslinking in all combinations [40]. This evidence concerns the gene TNFSF10 and cancer.